A 58-year-old woman with a history of intravenous heroin use and chronic inactive hepatitis B virus (HBV) infection with a low serum HBV DNA value, normal liver enzyme values, and no evidence of cirrhosis presented to the emergency department with sudden onset of painless jaundice and 8 days of malaise. Her last intravenous heroin use occurred 9 days prior to presentation. She was not taking any prescription or herbal medications and had not been prescribed suppressive antiviral medication for chronic HBV infection. She reported no history of travel outside the US and no raw meat ingestion. Her vital signs, mentation, and physical examination were normal except for scleral icterus (Figure). Results of blood testing were negative for hepatitis C virus RNA, anti–hepatitis A IgM, and HIV antibody. Other selected laboratory values are shown in the Table. A liver ultrasound performed 6 months prior to presentation and a repeat liver ultrasound with Doppler revealed no abnormalities.
Please finish quiz first before checking answer.
Read the answer below and download your certificate.
Read the discussion below and retake the quiz.
Hepatitis D superinfection
D. Order testing for hepatitis delta virus (HDV) IgM and IgG antibodies and, if positive, test for HDV RNA
The key to the correct diagnosis is recognition that the most likely cause of sudden-onset jaundice and newly elevated aminotransferase and bilirubin levels in a patient with intravenous drug use and chronic HBV infection without acute hepatitis A or C virus infection is HDV. Choice A is incorrect because HIV does not typically cause this level of aminotransferase and bilirubin elevation. Hepatitis E (choice B) is unlikely because the patient has never traveled outside the US and has not eaten raw meat. Anti–smooth muscle antibody testing (choice C) is helpful to diagnose autoimmune hepatitis, but this is not the most likely diagnosis in a patient with chronic HBV infection and intravenous drug use.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Brian L. Pearlman, MD, Wellstar Atlanta Medical Center, Center for Hepatitis C, 285 Boulevard NE, Ste 525, Atlanta, GA 30312 (Brianpearlman3@hotmail.com).
Published Online: June 13, 2022. doi:10.1001/jama.2022.8384
Conflict of Interest Disclosures: Dr Pearlman reported serving on the speakers bureau and an advisory board of Gilead Sciences for viral hepatitis–related topics. Gilead has a nonapproved medication in clinical trials for delta hepatitis.
Additional Contributions: We thank the patient for providing permission to share her information.
You currently have no searches saved.
You currently have no courses saved.